Particularly, three robust molecular alterations, namely 1p/19q codeletion and IDH and TERT promoter mutations, were used to categorize five principal molecular groups of gliomas with distinct clinical traits and mechanisms of carcinogenesis [2]. This evidence concerns the gene IDH2 and central nervous system cancer.